首页> 外文OA文献 >ACCOMPLISH study: challenging the choice of antihypertensive medications in systolic hypertensive patients with high cardiovascular risk
【2h】

ACCOMPLISH study: challenging the choice of antihypertensive medications in systolic hypertensive patients with high cardiovascular risk

机译:完成研究:在具有高心血管风险的收缩期高血压患者中挑战抗高血压药物的选择

摘要

Arterial hypertension is an important cardiovascular risk factor. The benefit drawn from decreasing and normalizing the blood pressure level is indisputable. The ACCOMPLISH study performed in patients older than 65 with systolic hypertension and a high cardiovascular risk pointed out the interest of well choosing the antihypertensive combination to reduce this risk beyond the decrease of blood pressure. The association of benazepril (an angiotensin converting enzyme inhibitor or ACEI) and amlodipine (a calcium antagonist) has shown significant early cardiovascular protection in such patients as compared to the classic association including the same ACEI and hydrochlorothiazide, in spite of the same target blood pressure reached. This important finding does not contest the interest of a well controlled blood pressure in hypertension, but probably will modify our first antihypertensive combination choice in the future in patients with such cardiovascular profile.
机译:动脉高压是重要的心血管危险因素。降低和正常化血压水平所带来的好处是无可争议的。 ACCOMPLISH研究在65岁以上的收缩期高血压和高心血管风险患者中进行,指出了很好选择降压药物组合以降低血压下降以外的风险的兴趣。与包括相同ACEI和氢氯噻嗪的经典关联(尽管目标血压相同)相比,苯那普利(一种血管紧张素转换酶抑制剂或ACEI)和氨氯地平(一种钙拮抗剂)的关联已显示出对此类患者的早期心血管保护作用显着。到达。这一重要发现并没有引起高血压患者对血压控制良好的兴趣,但将来可能会改变具有此类心血管特征的患者的首个抗高血压组合选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号